ERS/ATS指南:COPD急性加重预防的药物治疗推荐
该指南由欧洲呼吸学会与美国胸科学会联合制定,采用GRADE方法系统评价证据,针对黏液溶解剂、长效抗胆碱能药、PDE-4抑制剂罗氟司特和大环内酯类治疗提出推荐,并对氟喹诺酮类治疗给出条件性反对推荐。除长效抗胆碱能药对比长效β2激动剂为强推荐外,其余推荐均为条件性。
要点
- 推荐黏液溶解剂、长效抗胆碱能药、罗氟司特和大环内酯类用于预防COPD急性加重。
- 对氟喹诺酮类预防COPD急性加重给出条件性反对推荐。
- 长效抗胆碱能药对比长效β2激动剂的推荐为强推荐,其余均为条件性推荐。
核心结论
- 指南为COPD急性加重预防的药物治疗提供循证推荐,多数推荐为条件性。
研究设计与样本
- 由欧洲呼吸学会与美国胸科学会联合制定,采用GRADE方法系统评价证据并形成推荐。
主要发现
- 推荐涉及黏液溶解剂、长效抗胆碱能药、PDE-4抑制剂罗氟米特和大环内酯类治疗。
- 对氟喹诺酮类治疗给出条件性反对推荐。
- 长效抗胆碱能药对比长效β2激动剂的推荐为强推荐,其余推荐均为条件性。
关键数值与推荐
- 所有推荐均为条件性,除长效抗胆碱能药对比长效β2激动剂为强推荐。
临床怎么用
- 临床可依据指南推荐选择黏液溶解剂、长效抗胆碱能药、罗氟司特或大环内酯类预防COPD急性加重。
- 不推荐使用氟喹诺酮类预防COPD急性加重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society.Comprehensive evidence syntheses were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of COPD experts.After considering the balance of desirable (benefits) and undesirable consequences (burden in the form of adverse effects and cost), quality of evidence, feasibility, and acceptability of various interventions, the Task Force made recommendations for mucolytic, long-acting muscarinic antagonist, phosphodiesterase-4 inhibitor (roflumilast) and macrolide therapy, as well as a conditional recommendation against fluoroquinolone therapy. All of the recommendations were conditional, except for a strong recommendation for the use of a long-acting antimuscarinic agent versus a long-acting β2-adrenergic, indicating that there was uncertainty about the balance of desirable and undesirable consequences of the intervention, and that well-informed patients may make different choices regarding whether to have or not have the specific intervention.The guideline summarises the evidence and provides recommendations for pharmacological therapy for the prevention of COPD exacerbations.
引用
- Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017. PMID: 28889106. doi:10.1183/13993003.02265-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。